Abstract

The ability to culture pathogenic organisms substantially enhances the quest for fundamental knowledge and the development of vaccines and drugs. Thus, the elaboration of a protocol for the in vitro cultivation of the erythrocytic stages of Plasmodium falciparum revolutionized research on this important parasite. However, for P. vivax, the most widely distributed and difficult to treat malaria parasite, a strict preference for reticulocytes thwarts efforts to maintain it in vitro. Cultivation of P. cynomolgi, a macaque-infecting species phylogenetically close to P. vivax, was briefly reported in the early 1980s, but not pursued further. Here, we define the conditions under which P. cynomolgi can be adapted to long term in vitro culture to yield parasites that share many of the morphological and phenotypic features of P. vivax. We further validate the potential of this culture system for high-throughput screening to prime and accelerate anti-P. vivax drug discovery efforts.

Details

Title
Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages
Author
Chua, Adeline C Y 1 ; Jessica Jie Ying Ong 2 ; Malleret, Benoit 3   VIAFID ORCID Logo  ; Suwanarusk, Rossarin 4 ; Kosaisavee, Varakorn 5 ; Zeeman, Anne-Marie 6 ; Cooper, Caitlin A 7 ; Tan, Kevin S W 8   VIAFID ORCID Logo  ; Zhang, Rou 8 ; Tan, Bee Huat 9 ; Siti Nurdiana Abas 9 ; Yip, Andy 9 ; Elliot, Anne 7 ; Joyner, Chester J 10 ; Jee Sun Cho 8 ; Breyer, Kate 11 ; Baran, Szczepan 11   VIAFID ORCID Logo  ; Lange, Amber 11 ; Maher, Steven P 7   VIAFID ORCID Logo  ; Nosten, François 12   VIAFID ORCID Logo  ; Bodenreider, Christophe 9 ; Yeung, Bryan K S 9 ; Mazier, Dominique 13 ; Galinski, Mary R 14 ; Dereuddre-Bosquet, Nathalie 15 ; Roger Le Grand 15 ; Kocken, Clemens H M 6 ; Rénia, Laurent 3   VIAFID ORCID Logo  ; Kyle, Dennis E 7   VIAFID ORCID Logo  ; Diagana, Thierry T 9 ; Snounou, Georges 16 ; Russell, Bruce 17   VIAFID ORCID Logo  ; Bifani, Pablo 18   VIAFID ORCID Logo 

 Singapore Immunology Network, A*STAR, Singapore, Singapore; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand; Novartis Institute for Tropical Diseases, Singapore, Singapore 
 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand; Novartis Institute for Tropical Diseases, Singapore, Singapore 
 Singapore Immunology Network, A*STAR, Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 
 Singapore Immunology Network, A*STAR, Singapore, Singapore; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand 
 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, Thailand 
 Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands 
 Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, USA 
 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 
 Novartis Institute for Tropical Diseases, Singapore, Singapore 
10  Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University, Atlanta, USA; Emory Vaccine Center, Emory University, Atlanta, USA 
11  Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East Hanover, USA 
12  Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford Old Road Campus, Oxford, UK 
13  Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; CIMI-Paris, INSERM, U1135, CNRS, Paris, France 
14  Emory Vaccine Center, Emory University, Atlanta, USA; Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, USA 
15  CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, Fontenay-aux-Roses, France 
16  Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; CIMI-Paris, INSERM, U1135, CNRS, Paris, France; CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, Fontenay-aux-Roses, France 
17  Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand 
18  Singapore Immunology Network, A*STAR, Singapore, Singapore; Novartis Institute for Tropical Diseases, Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK 
Pages
1-13
Publication year
2019
Publication date
Aug 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2272204190
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.